Lupin Limited and Zydus Lifesciences Limited have inked a licensing and supply agreement to co-market Zydus’ innovative Semaglutide Injection (15 mg/3 ml) in a reusable pen device, aiming to widen the availability of this GLP-1 therapy for type 2 diabetes and weight management across India.
The pact grants Lupin semi-exclusive rights to promote the injectable under brands Semanext® and Livarise®, complementing Zydus’ existing labels SEMAGLYN™, MASHEMA™ and ALTERME™. Lupin will provide upfront fees and milestone payments to Zydus, leveraging its market reach and Zydus’ development expertise to address rising rates of metabolic disorders.
Nilesh Gupta, Managing Director of Lupin, highlighted the strategic fit. “Our partnership with Zydus to market Semaglutide injection in India is a significant step in strengthening our commitment to providing advanced treatment options for cardio-metabolic diseases,” he said. “As GLP-1 therapies continue to redefine treatment standards globally, this collaboration enhances our diabetes portfolio and reinforces our focus on addressing unmet patient needs.”
Dr. Sharvil Patel, Managing Director of Zydus Lifesciences, emphasised patient-centric design. “Our life-changing discoveries are empowering patients to live healthier, more fulfilling lives. Keeping patients’ needs and convenience at the very core, the innovative pen device we are offering is designed to make therapy simpler and improve quality of life,” he noted. The tie-up, he added, broadens reach for this novel delivery system nationwide.
Semaglutide serves adults with uncontrolled type 2 diabetes alongside diet and exercise, either as monotherapy when metformin proves unsuitable or combined with other antidiabetics. It also aids weight control in those with BMI over 30 kg/m² (obesity) or 27 kg/m² (overweight) plus comorbidities like hypertension, diabetes or dyslipidaemia, paired with calorie reduction and activity.
This collaboration arrives amid surging diabetes prevalence in India, where over 100 million cases strain healthcare resources. GLP-1 agonists like Semaglutide have transformed management by improving glycaemic control and promoting sustained weight loss, yet affordability and access lag in tier-2 and rural markets. The reusable pen simplifies dosing over vials, boosting adherence for busy patients.
Lupin and Zydus, both Indian pharma heavyweights, deepen their portfolios in endocrinology through this move. Lupin gains a foothold in high-growth injectables, while Zydus amplifies volumes via Lupin’s 10,000-plus doctor network. Financial terms remain undisclosed beyond the fee structure.
The deal underscores industry trends toward partnerships for complex biologics, mirroring global plays like Novo Nordisk’s Ozempic dominance. For Indian patients, it promises competitive pricing and supply stability amid regulatory nods for biosimilars.
